Product information and disease descriptionProduct descriptionProduct information
Indication
3 evidence topics · 5 sources
Proposed indication under FDA review: adults with obstructive sleep apnea
Intended disease severity range: mild, moderate, and severe
Phase 3 population: adults intolerant to or refusing PAP therapy
“SynAIRgy enrolled adults with mild-to-severe OSA who were intolerant to or refused PAP therapy into a randomized, double-blind, placebo-controlled, 26-week parallel-arm trial of AD109 vs placebo across 69 centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote